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Abstract 
Ischemic stroke is a serious disease leading to significant morbidity and mortality. 
Multifocal and recurrent strokes are usually caused by embolic diseases, i.e. atrial 
fibrillation, but rare causes like cerebral vasculitis and clotting disorders are also well 
known. Here we report on two patients suffering from the very rare intravascular large B-
cell lymphoma leading to multifocal and recurrent strokes in the brain and spinal cord as 
the prominent neurological symptom. The difficulties and the need for diagnostic brain 
biopsy in making an ‘in vivo’ diagnosis in this particular disease are outlined. 
Furthermore, the prerequisite for an interdisciplinary approach in these patients is 
strongly emphasized. Delayed diagnosis for several reasons was the most probable cause 
for cerebral relapse leading to death in one patient a few months after diagnosis. 
Conversely, early initiation of immunochemotherapy with a classical lymphoma schedule 
(R-CHOP) led to long-lasting remission of the disease in the other patient. With this 
report we like to improve alertness to intravascular large B-cell lymphoma as a cause for 
multifocal and recurrent strokes. 
 Case Rep Neurol 2011;3:278–283 
DOI: 10.1159/000334130 
Published online: 
October 24, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–680X 
www.karger.com/crn   
 
 
 
279
Introduction 
Ischemic stroke is the leading cause for morbidity and mortality worldwide [1]. Large- 
and small-vessel arteriopathy as well as atrial fibrillation are the prominent risk factors for 
cerebral stroke. However, besides other rare etiologies, occlusion of small brain arteries is 
very rarely caused by the malignant intravascular lymphoma, which was first described in 
1959 as ‘angioendotheliomatosis proliferans systemisata’ [2]. It is characterized by 
intravascular growth of neoplastic CD20-positive large B cells [3]. Clotting of neoplastic 
lymphoid cells especially in the capillaries leads to disseminated ischemic lesions in 
different organs, i.e. in the brain [4]. The exclusively intravascular localization of this 
lymphoma is attributed to a deficient property of extravasation, most probably due to a 
loss of the two adhesion molecules ICAM-1 (CD54) and beta-1 integrin (CD29). Since 
2001, the intravascular large B-cell lymphoma (IVLBCL) has been recognized as an entity 
in the WHO classification. The estimated annual incidence is about 0.5–1/1,000,000 
population. In half of the patients the diagnosis can only be made postmortem. CNS and 
skin are by far the most frequently affected sites (68%). Liver, spleen and bone marrow are 
involved to a much lesser extent. The reason of this neuroectodermal tropism remains 
elusive. A limited form with only cutaneous involvement exists chiefly in younger 
women. They have a far better prognosis than patients with multiorganic disease [3]. In 
contrast to the ‘Western’ type of IVLBCL, the ‘Asian’ variant shows preferentially 
hepatosplenic involvement and is associated with a hemaphagocytic syndrome 
accompanied by prominent thrombocytopenia. Interestingly, CNS and skin are rarely 
involved in the ‘Asian’ type of IVLBCL, suggesting a different spectrum of the disease. To 
improve the alertness among neurologists for this rare disease, we report two cases 
initially suffering from stroke symptoms, where the challenging ‘in vivo’ diagnosis of 
IVLBCL was histologically proven due to an interdisciplinary crusade. 
Case Report 
Case 1 
A 56-year-old formerly healthy man developed a progressive diffuse encephalopathic syndrome 
including cognitive impairment, disorientation, left hemiparesis and symptomatic epilepsy over more 
than eight month. Initial brain MRI showed disseminated subcortical T2-hyperintense lesions without 
gadolinium enhancement. CSF analysis revealed a normal protein level and borderline pleocytosis. The 
patient was treated with steroids, but repeated tapering provoked recurrence of the encephalopathic 
syndrome. After acute deterioration of the left hemiparesis suggesting an acute stroke, he was admitted 
to our hospital. Brain MRI now demonstrated numerous acute and subacute as well as old ischemic 
infarcts in different arterial territories. Laboratory workup showed an elevated lactate dehydrogenase 
(LDH) level (355 U/l), red and white cell count and platelets were unremarkable, but CSF now 
contained slightly increased total protein levels (0.68 g/l). No other organ alteration was found by CT 
scans of the lung and abdomen. In the next days, the patient suffered from multiple further strokes in 
different arterial territories despite therapy with aspirin, low-dose heparin and high doses of steroids. 
The follow-up brain MRI examination showed new strokes again in different arterial territories (fig. 1a–
c). ECG and echocardiography were unremarkable. Conventional cerebral angiography was not 
suggestive of vasculitis. Because of the progressive multifocal cerebral manifestations, we decided to 
perform a brain biopsy of the right parietal lobe ten days after admission. This biopsy revealed the 
surprising diagnosis of an IVLBCL (fig. 1d). Standard immunochemotherapy including rituximab (375 
mg/m
2) combined with cyclophosphamide, vincristine, doxorubicin and prednisolone (R-CHOP-14) as 
standard regimen for peripheral diffuse large B-cell lymphoma led to complete remission accompanied 
by a dramatic neurological improvement after six cycles of R-CHOP-14 and two additional cycles of Case Rep Neurol 2011;3:278–283 
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rituximab. Of note, due to the intravascular localization of the lymphoma, neither intrathecal nor 
systemic chemotherapy with significant penetration into the CNS (such as high-dose cytarabine or 
methotrexate) were applied. Complete remission is currently ongoing 26 month after the initial 
diagnosis. 
Case 2 
A 61-year-old woman was admitted to the emergency department with an acute onset of a left 
hemiparesis and a right-sided hemianopsia. Contrast-enhanced CT scan of the brain including a CT 
perfusion study revealed a perfusion deficit in the territory of the left posterior artery without evidence 
of arterial occlusion on CT angiography. Furthermore she experienced a complex partial seizure with 
myoclonic jerks of the right hand and a speech arrest. Under the suspicion of an ischemic stroke, i.v. 
thrombolysis with rtPA (0.9 mg/kg) was immediately administered and antiepileptic therapy with 
lorazepam and levetiracetam installed. Laboratory workup showed thrombocytopenia (131 G/l), 
elevated LDH (580 U/l) and elevated liver enzymes (GGT 55 U/l, AST 50 U/l). Weight loss of about 10 
kg in the previous 6 months and a depression was reported. She had a history of smoking. Previous 
diagnostic workup revealed unspecific infiltrations of the lung parenchyma on a chest CT scan without 
evidence of lung cancer. Hepatosplenomegaly and suspicious abdominal skin thickening were 
additionally described. On the next day she had fully recovered from the neurological symptoms. An 
MRI scan of the brain showed a wedge-shaped hyperintense lesion in the right parietal lobe without 
gadolinium enhancement (fig. 2a–c). Surprisingly, it additionally showed an asymptomatic T2 
hyperintensity of the pontine brainstem (not shown). No common risk factor for central pontine 
myelinolysis was present. Under the working diagnosis of a multi-organ disease, bronchoscopic lung 
biopsy, hepatic and abdominal skin biopsy, CSF analysis and multiple laboratory workup including 
infectious and paraneoplastic parameters did not lead to a definite diagnosis. Unfortunately, a brain, 
liver or spleen biopsy was refused. With the hypothesis of a systemic autoimmune disease, she was 
symptomatically treated with tapered doses of steroids and her condition greatly improved. After four 
weeks she was readmitted with an acute conus medullaris syndrome with urine incontinence, flaccid 
paraparesis and areflexia and was treated with repeated cycles of plasmapheresis under the diagnosis of 
an accompanying acute inflammatory demyelinating polyneuropathy (AIDP). Later on, the spinal 
affection turned out to be most probably of ischemic origin. As her condition worsened, diagnostic 
splenectomy was now performed and revealed the diagnosis of an IVLBCL (fig. 2d). Immediately, she 
was treated with intravenous immunochemotherapy (R-CHOP-14) [4]. Despite a serological response 
of the serum LDH, the neurological condition showed only minor improvements. After 5 cycles she 
died a few months after her first stroke due to a fulminant cerebral relapse. 
Discussion 
Western type IVLBCL is a very rare disease characterized by a multifocal CNS and 
multisystemic clinical presentation. Subacute diffuse and unspecific symptoms make the 
diagnosis of IVLBCL ‘in vivo’ a real challenge. The hallmark of IVLBCL with cerebral 
involvement is the triad of a subacute encephalopathy, multiple strokes and elevated 
serum LDH. Cerebral vasculitis, septic encephalopathy or infections of the CNS are the 
main differential diagnoses, while IVLBCL is mostly not under consideration in the first 
place. 
Patients suffering from clinical syndromes as described are often treated with steroids 
based on the clinical and radiological diagnosis of a cerebral vasculitis, which is rarely 
proven by brain biopsy. In patients with IVLBCL, as presented here, blind 
immunosuppressive treatment without biopsy may critically delay the final diagnosis of 
IVLBCL due to a transient remission of neurological symptoms. Moreover, 
corticosteroids alone are clearly insufficient to substantially treat this disease as 
demonstrated by our presented cases. Case Rep Neurol 2011;3:278–283 
DOI: 10.1159/000334130 
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Brain biopsy is the diagnostic procedure of choice in suspected IVLBCL affecting the 
CNS, as CSF analysis, brain MRI/CT scans, MR or CT angiography and even 
conventional cerebral angiography lack specificity to differentiate IVLBCL from other 
diseases like cerebral vasculitis [6]. This has especially been taken into account since 
immunosuppressive therapy without prior histological diagnosis has been reported to 
lead to fatal outcome in overlooked infectious brain diseases [7]. 
In contrast to other organs, brain biopsy is considerably more rarely performed. 
Despite low morbidity even in specialized centers, only 4–5 brain biopsies are reported 
per year for suspected nonneoplastic disease [8]. The diagnostic yield of brain biopsy in 
multifocal CNS diseases like cerebral vasculitis is reported to be as high as 75% [9]. In a 
retrospective analysis of 64 patients over a time period of 15 years, a specific diagnosis was 
made in 34 patients (53%) [8]. Although half of the brain biopsies did not lead to a 
definite diagnosis, this procedure, at least, excludes a CNS infection. This is of utmost 
importance according to the choice of the appropriate immunosuppressive therapy. 
IVLBCL and primary CNS lymphoma (PCNSL) both represent rare entities of high 
grade B-cell lymphomas affecting the CNS. Due to the different localization of both 
entities – PCNSL growing on the parenchymal side protected by the blood-brain barrier 
(BBB) and IVLBCL growing inside the vessel – the adequate chemotherapeutic approach 
is strikingly different. The therapy of choice in PCNSL consist of high-dose methotrexate 
and/or cytarabine, with or without whole-brain radiotherapy as these drugs penetrate into 
the brain parenchyma by crossing the BBB in cytotoxic concentrations [5]. In contrast, 
the intravascular location of IVLBCL does not require drugs which are able to cross the 
BBB. Therefore, and given the favorable toxicity profile, standard R-CHOP chemo-
immunotherapy without the use of high-dose methotrexate and/or cytarabine is an 
adequate and active therapy with favorable toxicity for patients suffering from CNS 
manifestations of IVLBCL [4]. 
In our patients, ischemic strokes were the prominent clinical condition which covered 
the diagnosis of the underlying IVLBCL for a considerably long time. Multiple acute and 
subacute strokes prompted us to perform a brain biopsy in case 1. Missing the exact 
diagnosis by a refused brain or spleen biopsy in case 2 led to a dramatic neurological 
decline with the emergence of a fatal conus medullaris syndrome. Despite of numerous 
cycles of R-CHOP-14 therapy the patient died due to fulminant cerebral progression. 
Unfortunately, a former skin biopsy from this patient retrospectively turned out to show 
diagnostic characteristics of IVLBCL (fig. 2e). Therefore, earlier appropriate treatment 
might have changed the outcome in a more favorable direction. 
In conclusion, IVLBCL affecting the brain is an extremely rare but life-threatening 
disease. It is characterized by multifocal and recurrent strokes. Early brain biopsy is of 
paramount importance to achieve the correct diagnosis. It can be performed with 
acceptable risks and may lead to the diagnosis of a potentially curative condition that 
would otherwise be missed with the consequence of a vital threat to the patient. 
Immunochemotherapy with R-CHOP-14, omitting classical chemotherapy regimens used 
for PCNSL, can substantially lead to the prevention of devastating strokes as well as 
ischemias in other organs and may induce durable complete remission as demonstrated 
in one case presented here. As IVLBCL is an extremely rare disease and the clinical 
presentation is unspecific, the correct diagnosis can easily be overlooked even in biopsies 
as demonstrated in case 2. Of note, the most important step to immediate and Case Rep Neurol 2011;3:278–283 
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appropriate treatment of the patients with a CNS involvement is to obtain and thoroughly 
evaluate brain tissue for a workup involving neurodegenerative, immunological, 
infectious and neoplastic aspects. 
 
 
 
 
 
 
Fig. 1. a–c Case 1. a T2-weighted axial MR image with diffuse leukoencephalopathy, older cortical 
infarct (arrow). b Diffusion-weighted image showing multiple acute and subacute medullary infarcts in 
both hemispheres. c Contrast-enhanced T1-weighted image demonstrating intact blood-brain barrier 
and absent enhancement of ischemic areas. d Brain biopsy (case 1): blastic lymphoid tumor cells within 
intracerebral vessels but not in the brain tissue (two mitotic figures). 
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Fig. 2. a–c Case 2. T2-weighted (a), fluid-attenuated inversion recovery (b) and diffusion-weighted (c) 
images showing a triangular shaped cortically based lesion with moderately restricted diffusion in the 
right parietal lobe suggestive of a subacute ischemic lesion. d Splenectomy specimen: blastic lymphoid 
tumor cells strictly confined to hilar blood vessels showing strong immunoreactivity with the pan-B cell 
marker CD20. e Skin biopsy: IVBCL infiltration in the deeper dermis. 
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